Shots: The P-II OPTIC study involves assessing three initial doses of Iclusig (15/30/45 mg) in 283 patients with CML in CF, or who had documented history of the presence of the T315I mutation after receiving any number of previous TKIs With an average follow-up of~ 21 mos., the interim analysis showed that maximum BCR- ABL1 […]Read More
